FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/02/2026
Voltar para busca
Dado oficial do USPTO
ABOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
20/02/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
18/01/2022
Data de registro
15/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/07/2025
Última transação
20/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
CN
Examinador
HARMON, RAYMOND E
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "ABOGEN".
Titulares e representantes
Titulares
Suzhou Abogen Biosciences Co., Ltd.
Representantes
THOMAS HOXIE HOXIE & ASSOCIATES LLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals for the treatment of viral diseases; human vaccine preparations; oral vaccine preparations; vaccines; immunostimulants; antivirals; pharmaceutical preparations for the treatment or prevention of cancerinfectious diseases; bacteriological preparations for medical purposes; vaccines against pneumococcal infections; vaccine preparations; all of the foregoing for use in the treatment or prevention of cancer and infectious disease
Classe 42
Cancer research for medical purposes; scientific investigations for medical purposesspecifically for treatment or prevention of cancer and infectious diseases; product quality testingspecifically for products for the treatment or prevention of cancer and infectious diseases; medical researchspecifically for treatment or prevention of cancer and infectious diseases; development of pharmaceutical preparations and pharmaceuticalsspecifically for treatment or prevention of cancer and infectious diseases; medical research servicesspecifically research for the treatment or prevention of cancer and infectious diseases; pharmaceutical research servicesspecifically for research for the treatment or prevention of cancer and infectious diseases; medicines research servicesspecifically research for the treatment or prevention of cancer and infectious diseases; research and development services relating to medicinesspecifically medicines for the treatment or prevention of cancer and infectious diseases; computer programming in the medical fieldspecifically relating to the treatment or prevention of cancer and infectious diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/02/2026
FIMP
FINAL DISPOSITION PROCESSED
05/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
15/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
15/07/2025
TMBN
TTAB RELEASE CASE TO TRADEMARKS
24/06/2025
OP.T
OPPOSITION TERMINATED NO. 999999
24/06/2025
OP.D
OPPOSITION DISMISSED NO. 999999
24/06/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/09/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/09/2023
RFNT
REFUSAL PROCESSED BY IB
19/04/2023
OP.I
OPPOSITION INSTITUTED NO. 999999
27/03/2023
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
22/03/2023
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
22/03/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
15/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/11/2022
PUBO
PUBLISHED FOR OPPOSITION
22/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/10/2022
RFNT
REFUSAL PROCESSED BY IB
21/09/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
26/08/2022
RFRR
REFUSAL PROCESSED BY MPU
26/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/08/2022
CNRT
NON-FINAL ACTION WRITTEN
16/08/2022
DOCK
ASSIGNED TO EXAMINER
10/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/04/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/04/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ABOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.